Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Research & Development (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Research & Development for 3 consecutive years, with $1.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Research & Development fell 17.27% year-over-year to $1.5 million, compared with a TTM value of $6.3 million through Dec 2024, down 29.51%, and an annual FY2024 reading of $6.3 million, down 29.51% over the prior year.
  • Research & Development was $1.5 million for Q4 2024 at Oramed Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $9.2 million in Q2 2022 and bottomed at $957000.0 in Q3 2023.
  • Average Research & Development over 3 years is $3.6 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 82.1% in 2023, then surged 134.27% in 2024.
  • Year by year, Research & Development stood at $7.3 million in 2022, then crashed by 75.73% to $1.8 million in 2023, then dropped by 17.27% to $1.5 million in 2024.
  • Business Quant data shows Research & Development for ORMP at $1.5 million in Q4 2024, $2.2 million in Q3 2024, and $1.4 million in Q2 2024.